Click on image to view larger version.

Figure 1 Individual and composite adverse event rates at 30 days (upper graph) and 1 year (lower graph) in patients achieving optimal percutaneous transluminal coronary angioplasty (PTCA) results randomized to pre-procedural abciximab administration (white bars) versus no pre-procedural abciximab. The p values for all two-way comparisons in both graphs are non-significant. TVR = target vessel revascularization.